company background image
2496 logo

Wuhan YZY Biopharma SEHK:2496 Stock Report

Last Price

HK$3.89

Market Cap

HK$754.1m

7D

-15.3%

1Y

-56.2%

Updated

08 Dec, 2024

Data

Company Financials

Wuhan YZY Biopharma Co., Ltd.

SEHK:2496 Stock Report

Market Cap: HK$754.1m

2496 Stock Overview

A biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. More details

2496 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Wuhan YZY Biopharma Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Wuhan YZY Biopharma
Historical stock prices
Current Share PriceHK$3.89
52 Week HighHK$9.06
52 Week LowHK$3.80
Beta0
11 Month Change-29.01%
3 Month Change-38.06%
1 Year Change-56.19%
33 Year Changen/a
5 Year Changen/a
Change since IPO-75.69%

Recent News & Updates

Is Wuhan YZY Biopharma (HKG:2496) Using Debt In A Risky Way?

Oct 02
Is Wuhan YZY Biopharma (HKG:2496) Using Debt In A Risky Way?

Recent updates

Is Wuhan YZY Biopharma (HKG:2496) Using Debt In A Risky Way?

Oct 02
Is Wuhan YZY Biopharma (HKG:2496) Using Debt In A Risky Way?

Shareholder Returns

2496HK BiotechsHK Market
7D-15.3%0.2%3.1%
1Y-56.2%-5.0%19.6%

Return vs Industry: 2496 underperformed the Hong Kong Biotechs industry which returned -5% over the past year.

Return vs Market: 2496 underperformed the Hong Kong Market which returned 19.6% over the past year.

Price Volatility

Is 2496's price volatile compared to industry and market?
2496 volatility
2496 Average Weekly Movement7.6%
Biotechs Industry Average Movement10.8%
Market Average Movement8.9%
10% most volatile stocks in HK Market18.9%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 2496 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2496's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010114Pengfei Zhouwww.yzybio.com

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma and other advanced solid tumors, small cell lung cancer, relapsed/refractory multiple myeloma, and HER2-positive solid tumors; and covid 19 indication, as well as wAMD, DME, and other ocular neovascularization-related diseases. The company was founded in 2010 and is based in Wuhan, China.

Wuhan YZY Biopharma Co., Ltd. Fundamentals Summary

How do Wuhan YZY Biopharma's earnings and revenue compare to its market cap?
2496 fundamental statistics
Market capHK$754.07m
Earnings (TTM)-HK$196.40m
Revenue (TTM)HK$8.63m

87.4x

P/S Ratio

-3.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2496 income statement (TTM)
RevenueCN¥8.07m
Cost of RevenueCN¥0
Gross ProfitCN¥8.07m
Other ExpensesCN¥191.60m
Earnings-CN¥183.53m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.95
Gross Margin100.00%
Net Profit Margin-2,275.35%
Debt/Equity Ratio241.0%

How did 2496 perform over the long term?

See historical performance and comparison